Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation (CDE) has accepted the Phase III clinical filing for its in-house developed OT-101-S, a treatment aimed at delaying or arresting child myopia. This development marks a significant step forward in the advancement of this novel therapeutic approach.
Low-Concentration Atropine Sulfate Eye Drops: Safety and Efficacy
Research indicates that low concentration atropine sulfate eye drops, such as those found in OT-101-S, demonstrate good tolerance, safety, and efficacy compared to high concentration (0.5% – 1%) atropine sulfate eye drops, which often report adverse events including photophobia and blurred vision. The low concentration formula offers a more tolerable and effective alternative for managing myopia in children.
Innovative Design of OT-101-S for Enhanced Compliance and Effectiveness
OT-101-S is designed with a unique two-chamber system, containing atropine sulfate concentrated solution and diluted solution for each dosage unit, both of which are preservative-free. Before use, the two chambers are mixed to create low concentration atropine sulfate eye drops. This innovative design not only makes the storage and use of OT-101-S more convenient but also significantly improves the product’s use compliance and effectiveness due to the neutral solution environment.-Fineline Info & Tech
